ClinicalTrials.gg
CompletedNCT05275998Updated Oct 22, 2025Results posted

TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals

A Phase 1/2 interventional study of TMB-365/TMB-380 in HIV-1-infection, sponsored by TaiMed Biologics Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-10-22.

Sponsored by TaiMed Biologics Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
51
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC-07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry. This study is designed to test various doses of the combination of the antibodies for safety and pharmacokinetics in suppressed subjects on cART. Once dosing is established based on safety and PK, the optimally dosed combinations will be assessed as maintenance therapy in HIV infected suppressed individuals discontinuing oral cART for 24 weeks.

Read the detailed description

This study is a phase 1b / 2 adaptive open-label dose escalation study of the combination of TMB-365 and TMB-380. This adaptive study design will be comprised of Sentinel Groups (N=10) and Core Groups (N=20). Safety and pharmacokinetic (PK) data obtained from Sentinel group participants will guide the conduct of Core Group execution.

Participants will be HIV-infected and suppressed for at least 6 months on continuous daily oral combination antiretroviral therapy (cART). Continuous is defined as no more than 3 consecutive days of missed cART. There are three doses of each antibody being explored, 2400 mg, 3200 mg, and 4800 mg.

Sentinel Groups Sentinel Groups will be comprised of 10 cART suppressed HIV-1 infected volunteers who receive a single IV dose of the combination of TMB-365 and TMB-380 while continuing cART.

Sentinel Group 1 will be dosed with 2400 mg of each antibody and will continue daily oral cART throughout the screening, infusion, and post-infusion observation period of 12 and be assessed for safety and pharmacokinetics.

Sentinel group 2 will dose both antibodies at 3200 mg. The third sentinel group will dose both antibodies at 4800 mg.

Criteria for safety of a dose of either TMB-365 or TMB-380 include:

i) No SAEs probably or definitely due to TMB-365 or TMB-380 ii) No more than one Grade 3 or Grade 4 adverse event probably or definitely related to TMB-365 or TMB-380 at any dose level.

Toxicity evaluations will be guided by the DAIDS Table for Grading Severity of Adult and Pediatric Adverse Events Version 2.1. The Common Terminology Criteria for Adverse Events (CTCAE) v. 5.0 scale will be used for assessment of any infusion reactions, or anaphylactic events.

PK targets:

i. TMB-365: serum levels >0.3 μg/mL ii. TMB-380: serum levels >65 μg/mL Should a dose of either antibody prove safe and at least 80% of subjects studied in a given Sentinel dose group meet specified safety and PK criteria, then a Core group of 20 subjects will be enrolled and treated with that dose of TMB-365 and TMB-380 as a stand-alone complete maintenance regimen for 24 weeks.

Safety must be established prior to any request for dose escalation to the next higher Sentinel dose group. A review of 14-day safety data in 7 of 10 subjects after infusion must be available for review prior to any request for dose escalation. Dose escalation may only occur with the approval of an independent Data Monitoring Committee (DMC).

The maximum dose of TMB-365 and TMB-380 that will be tested in Sentinel groups is 4800 mg.

The first 3 subjects in each Sentinel group will be treated at designated sites selected for demonstration of expertise in the use of monoclonal antibody therapy. Subjects will remain at the study site for 3 hours post-infusion for monitoring of vital signs every 15 minutes beginning 15 minutes prior to the infusion of TMB-365 and TMB-380 as well as observation for the presence of infusion reactions. Should the infusions be well tolerated and no Grade 3 or 4 AEs, or SAE's occur due to study drugs within 7 days of infusion, then the remaining 7 subjects in that group may be recruited/treated. These subjects will remain at study sites for 1 hour post-infusion for monitoring of vital signs and the presence of infusion reactions.

Core Group Subjects There will be one Core Group comprised of 40 cART suppressed HIV-1 infected volunteers and will receive multiple IV doses of the combination of TMB-365 and TMB-380 as a stand-alone maintenance regimen for 24 weeks. Oral cART will be restarted in the clinic at the Week 24 visit.

Core group participants will complete the study at Day 196, 4 weeks after reinstituting oral cART. Sentinel group participants at the same dosing level may be enrolled in a Core group if infusions are well tolerated and the subject is willing to discontinue oral cART.

Core Group study group 1 will begin with the doses of each antibody that prove safe and meet PK targets.

Regimen in Core Group participants based on PK modeling include:

TMB-365: 4800 mg q 8 weeks. TMB-380: 4800 mg q 8weeks. Sentinel Group participants that wish to participate in Core Groups must repeat all screening procedures including signing a second Informed Consent Form.

02

Conditions studied

  • HIV-1-infection

Keywords

  • HIV-1 treatment, monoclonal antibodies
03

In context

Lead sponsor

TaiMed Biologics Inc. is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:Participants must meet all of the following criteria to be included in the study:

  1. Male or female at least 18 years of age and no greater than 60 years on the day of Screening.
  2. Asymptomatic -1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by Geenius™ or a second antibody test by a method other than the initial rapid HIV and/or E/CIA test, or by HIV-1 antigen, plasma HIV-1 RNA viral load at or piror to screening.
  3. On continuous suppressive cART for 6 months prior to screening with one documented HIV-1 RNA level below the level of detection within 3 months of screening. Continuous cART is defined as no interruptions greater than 3 consecutive days. cART is defined as a DHHS recommended regimen. Study participants should be on a stable regimen, at least 3 months.
  4. Screening plasma HIV-1 RNA below the limit of detection.
  5. >350 cells/mm3
  6. Laboratory values obtained within 30 days prior to the first dose:

    • > 10.0 g/dL;
    • count ≥ 100,000/mm3;
    • ≥ 1,000/mm3;
    • Serum (AST) and alanine aminotransferase (ALT) \< 1.5 x (ULN); and
    • (CrCl) of ≥ 50 mL/min.
  7. Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study.
  8. In the opinion of the principal investigator or designee, has understood the information provided; written needs to be given before any study-related procedures are performed.
  9. Females of , sexually active with a male sex partner, must agree to use one effective method of from the time of signing the consent to completion of the study, and agree to pregnancy testing as per the Schedule of Events and Procedures. Females of childbearing potential are female participants who are not surgically sterile (no history of bilateral tubal ligation, hysterectomy, or bilateral salpingo-oophorectomy), are not (at least one year without menses), and are not otherwise sterile by medical evaluation.

    -

Exclusion Criteria:

Participants having or meeting any of the following conditions or characteristics will be excluded from the study:

  1. Suppressed subjects who have not been on a stable DHHS recommended cART regimen for at least 3 months.
  2. Receipt of any monoclonal antibody for the treatment or prevention of HIV infection except for Sentinel subjects eligible for enrollment into Core groups.
  3. Suppressed subjects receiving cabotegravir and rilpivirine intramuscularly as maintenance therapy for HIV-1 infection.
  4. Pregnant, planning a pregnancy during the trial period, or lactating.
  5. Known allergy/sensitivity or any to components of the study drug or its formulation, or known allergy to a MAb.
  6. Major psychiatric illness including any history of schizophrenia or severe psychosis, uncontrolled bipolar disorder requiring acute therapy, or suicide attempt in the previous three years.
  7. Serious illness requiring systemic treatment and/or hospitalization within 21 days prior to the first dose.
  8. Receipt of immunomodulatory agents (e.g., interleukins, interferons, cyclosporine, high dose systemic ), HIV vaccine, systemic cytotoxic chemotherapy, or therapy within 180 days prior to the first dose.
  9. Any chronic or acute medical condition, including chronic Hepatits B infection, chronic infection with viremia, and drug use and alcohol abuse, which in the opinion of the investigator would interfere with evaluation of the study drug.
  10. Lack of adequate venous access.
  11. Individuals who have experienced virologic failure during treatment with two or more cART treatment regimens and those being treated with regimens containing either ibalizumab, enfuvirtide, maraviroc, and fostemsavir. Note that a change in treatment regimen for intolerance does not meet criteria for virologic failure.

    -

Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Sentinel Group 1

    10 HIV-1 infected subjects will receive one infusion of 2400 mg of each antibody, TMB-365 and TMB-380 and be followed for safety and pharmacokinetics. Oral suppressive cART will be continued throughout the course of the study participation.

    Drug: TMB-365/TMB-380

  • Experimental
    Sentinel Group 2

    10 HIV-1 infected subjects will receive one infusion of 3200 mg of each antibody, TMB-365 and TMB-380 and be followed for safety and pharmacokinetics. Oral suppressive cART will be continued throughout the course of the study participation.

    Drug: TMB-365/TMB-380

  • Experimental
    Sentinel Group 3

    10 HIV-1 infected subjects will receive one infusion of 4800 mg of each antibody, TMB-365 and TMB-380 and be followed for safety and pharmacokinetics. Oral suppressive cART will be continued throughout the course of the study participation.

    Drug: TMB-365/TMB-380

  • Experimental
    Core Group 1

    20 HIV-1 infected subjects will receive 4800 mg infusions of each antibody, TMB-365 and TMB-380 every 8 weeks and be followed for safety, pharmacokinetics, and ability to maintain antiviral activity. Oral suppressive cART will be discontinued for 24 weeks then resumed at week 24 with follow-up at week 28.

    Drug: TMB-365/TMB-380

Interventions

  • DrugTMB-365/TMB-380

    Monoclonal antibodies to be given intravenously

    Also known as: TMB-380 is also known as VRC07-523-LS

06

What researchers measure

Primary outcomes

  1. Safety of TMB-365 and TMB-380 Given Intravenously (Sentinel and Core)

    Grade 3, Grade 4, Serious Adverse reactions related to TMB-365 and TMB-380 infusions

    Time frame: 12 weeks (Sentinel Group 1), 16 weeks (Sentinel Group 2, 3), 28 weeks (Core Group)

  2. Pharmacokinetics of a Single Dose TMB-365 Given Intravenously (Sentinel)

    In the Sentinel Group, participants received a single dose of TMB-365 and TMB-380 at 2400 mg, 3200 mg, or 4800 mg each. TMB-365 concentrations were measured using a validated ELISA, and the Week 8 concentration was used to guide dose selection for the Core Group.

    Time frame: Week 8

  3. Pharmacokinetics of TMB-365 Given Intravenously Every 8 Weeks (Core)

    Core Group participants received 4800 mg every 8 weeks.TMB-365 concentrations were measured using a validated ELISA. Trough concentrations are reported.

    Time frame: Week 8, 16, and 24

  4. Pharmacokinetics of a Single Dose TMB-380 Given Intravenously (Sentinel)

    In the Sentinel Group, participants received a single dose of TMB-365 and TMB-380 at 2400 mg, 3200 mg, or 4800 mg each. TMB-380 concentrations were measured using a validated ELISA, and the Week 8 concentration was used to guide dose selection for the Core Group.

    Time frame: Week 8

  5. Pharmacokinetics of TMB-380 Given Intravenously Every 8 Weeks (Core)

    Core Group participants received 4800 mg every 8 weeks.TMB-380 concentrations were measured using a validated ELISA. Trough concentrations are reported.

    Time frame: Weeks 8, 16, and 24

  6. Antiviral Activity of the Combination of TMB-365 in Combination With TMB-380 as Maintenance Therapy (Core)

    Plasma HIV-1 level below 50 copies/mL in study subjects at week 24 during maintenance therapy with TMB-365/TMB-380 infusions in Core Subjects only.

    Time frame: Week 24

Secondary outcomes

  1. Resistance to TMB-365 and TMB-380 (Core)

    Phenotype and genotype of HIV-1 variants in study subjects who fail to maintain antiviral response on infusions of TMB-365 and TMB-380

    Time frame: 24 weeks

07

Results

Posted Oct 22, 2025

Participant flow

Participant flow — Overall Study
MilestoneSentinel Group 1Sentinel Group 2Sentinel Group 3Core Group 1
Started10101021
Completed1010918
Not completed0013
Withdrew: Adverse event0001
Withdrew: Withdrawal by subject0001
Withdrew: Physician decision0001
Withdrew: Protocol violation0010

Outcome measures

PrimarySafety of TMB-365 and TMB-380 Given Intravenously (Sentinel and Core)

Grade 3, Grade 4, Serious Adverse reactions related to TMB-365 and TMB-380 infusions

Time frame:
12 weeks (Sentinel Group 1), 16 weeks (Sentinel Group 2, 3), 28 weeks (Core Group)
Reported as:
Count of participants · Participants
Safety of TMB-365 and TMB-380 Given Intravenously (Sentinel and Core)
ParticipantsSentinel Group 1Sentinel Group 2Sentinel Group 3Core Group 1
Safety of TMB-365 and TMB-380 Given Intravenously (Sentinel and Core)0000
PrimaryPharmacokinetics of a Single Dose TMB-365 Given Intravenously (Sentinel)

In the Sentinel Group, participants received a single dose of TMB-365 and TMB-380 at 2400 mg, 3200 mg, or 4800 mg each. TMB-365 concentrations were measured using a validated ELISA, and the Week 8 concentration was used to guide dose selection for the Core Group.

Time frame:
Week 8
Reported as:
Mean · mcg/mL
Pharmacokinetics of a Single Dose TMB-365 Given Intravenously (Sentinel)
mcg/mLSentinel Group 1Sentinel Group 2Sentinel Group 3
Pharmacokinetics of a Single Dose TMB-365 Given Intravenously (Sentinel)0.50 ± 1.231.91 ± 3.1915.13 ± 13.45
PrimaryPharmacokinetics of TMB-365 Given Intravenously Every 8 Weeks (Core)

Core Group participants received 4800 mg every 8 weeks.TMB-365 concentrations were measured using a validated ELISA. Trough concentrations are reported.

Time frame:
Week 8, 16, and 24
Reported as:
Mean · mcg/mL
Pharmacokinetics of TMB-365 Given Intravenously Every 8 Weeks (Core)
mcg/mLCore Group
Week 8 pre-dose concentration29.54 ± 30.18
Week 16 pre-dose concentration29.12 ± 31.25
Week 24 trough concentration29.11 ± 35.94
SecondaryResistance to TMB-365 and TMB-380 (Core)

Phenotype and genotype of HIV-1 variants in study subjects who fail to maintain antiviral response on infusions of TMB-365 and TMB-380

Time frame:
24 weeks
Reported as:
Count of participants · Participants
Resistance to TMB-365 and TMB-380 (Core)
ParticipantsCore Group 1
Resistance to TMB-365 and TMB-380 (Core)0
PrimaryPharmacokinetics of a Single Dose TMB-380 Given Intravenously (Sentinel)

In the Sentinel Group, participants received a single dose of TMB-365 and TMB-380 at 2400 mg, 3200 mg, or 4800 mg each. TMB-380 concentrations were measured using a validated ELISA, and the Week 8 concentration was used to guide dose selection for the Core Group.

Time frame:
Week 8
Reported as:
Mean · mcg/mL
Pharmacokinetics of a Single Dose TMB-380 Given Intravenously (Sentinel)
mcg/mLSentinel Group 1Sentinel Group 2Sentinel Group 3
Pharmacokinetics of a Single Dose TMB-380 Given Intravenously (Sentinel)59.59 ± 14.5963.05 ± 16.4786.43 ± 24.09
PrimaryPharmacokinetics of TMB-380 Given Intravenously Every 8 Weeks (Core)

Core Group participants received 4800 mg every 8 weeks.TMB-380 concentrations were measured using a validated ELISA. Trough concentrations are reported.

Time frame:
Weeks 8, 16, and 24
Reported as:
Mean · mcg/mL
Pharmacokinetics of TMB-380 Given Intravenously Every 8 Weeks (Core)
mcg/mLCore Group 1
Week 8 pre-dose concentration83.72 ± 25.13
Week 16 pre-dose concentration91.48 ± 21.93
Week 24 trough concentration107.12 ± 28.44
PrimaryAntiviral Activity of the Combination of TMB-365 in Combination With TMB-380 as Maintenance Therapy (Core)

Plasma HIV-1 level below 50 copies/mL in study subjects at week 24 during maintenance therapy with TMB-365/TMB-380 infusions in Core Subjects only.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Antiviral Activity of the Combination of TMB-365 in Combination With TMB-380 as Maintenance Therapy (Core)
ParticipantsCore Group 1
Antiviral Activity of the Combination of TMB-365 in Combination With TMB-380 as Maintenance Therapy (Core)16

Adverse events

Collected over Adverse events were collected for the duration of the study which included a screening period of 6 weeks, 12 weeks for the 2400 mg and 3200 mg single dose group, 16 weeks for the 4800 mg single dose group, and 28 weeks for the 4800 mg multiple dose group (infusions for 24 weeks and 4 weeks of follow up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sentinel Group 10/10 (0%)0/10 (0%)9/10 (90%)
Sentinel Group 20/10 (0%)0/10 (0%)9/10 (90%)
Sentinel Group 30/10 (0%)0/10 (0%)5/10 (50%)
Core Group 10/21 (0%)0/21 (0%)14/21 (66.7%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventSentinel Group 1Sentinel Group 2Sentinel Group 3Core Group 1
COVID-19Infections and infestations3/101/100/101/21
fatigueGeneral disorders1/102/100/104/21
hypersensitivityImmune system disorders0/102/100/100/21
upper respiratory infectionInfections and infestations0/101/102/102/21
rashSkin and subcutaneous tissue disorders0/101/101/103/21
headacheNervous system disorders0/101/100/103/21
papulesSkin and subcutaneous tissue disorders1/101/100/100/21
syphilisInfections and infestations0/100/101/100/21
streptococcal pharyngitisInfections and infestations0/100/101/100/21
eczemaSkin and subcutaneous tissue disorders1/100/100/100/21

Baseline characteristics

Study subjects are all HIV-infected, cART treated and suppressed on therapy for at least 6 months

Age, Continuous
Age, Continuous(years)Sentinel Group 1Sentinel Group 2Sentinel Group 3Core Group 1Total
Mean44.5 ± 7.943.1 ± 12.144 ± 10.149.3 ± 12.446.1 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)Sentinel Group 1Sentinel Group 2Sentinel Group 3Core Group 1Total
Female01113
Male10992048
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sentinel Group 1Sentinel Group 2Sentinel Group 3Core Group 1Total
American Indian or Alaska Native00000
Asian10113
Native Hawaiian or Other Pacific Islander00000
Black or African American132511
White7671434
More than one race10012
Unknown or Not Reported01001
08

Study locations

6 sites
  • Quest Clinical Research
    San Francisco, California 94115, United States
  • CAN Community Health
    Fort Lauderdale, Florida 33316, United States
  • Midway Immunology and Research Center
    Ft. Pierce, Florida 34892, United States
  • Orlando Immunology Center
    Orlando, Florida 32803, United States
  • North Texas Infectious Disease Consultants
    Dallas, Texas 75246, United States
  • Crofoot Research Center, Inc.
    Houston, Texas 77098, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Nov 2024, 28 months.

Results were first posted in Oct 2025, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2022
First posted
Mar 11, 2022
StartActual
Jul 5, 2022
Primary completionActual
Nov 20, 2024
CompletionActual
Nov 20, 2024
Results first posted
Oct 22, 2025
Last update
Oct 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05275998
Lead sponsor
TaiMed Biologics Inc.
Responsible party
Sponsor
First posted
Mar 11, 2022
Start date
Jul 5, 2022
Primary completion
Nov 20, 2024
Completion
Nov 20, 2024
Results posted
Oct 22, 2025
Last update
Oct 22, 2025

Study contacts

Jay Lalezari, MD
principal investigator · Quest Clinical Research

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion